Roopa Mehta is an endocrinologist and researcher in the Department of Endocrinology and Metabolism at El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) in Mexico City, Mexico. She is the director of the lipid clinic and the cardiovascular laboratory, and an associate professor in the endocrinology residency programme. She is also a principal investigator for phase 3 clinical trials and has completed a PhD in Medical Sciences.
She completed her medical training at the United Medical and Dental Schools of Guy’s and St Thomas’ Hospital. She obtained MRCP in 2000 and trained as an endocrinologist at INCMNSZ. On completing the residency programme, she sub-specialised in diabetes and metabolism, and gained further clinical and investigative experience at the Joslin Diabetes Center in the USA.
Dr Mehta’s research interests focus on type 2 diabetes (clinical investigation), metabolic syndrome and lipid metabolism (in particular evaluation of cardiovascular risk and familial hypercholesterolemia). She has recently completed a research attachment at Imperial College, London, focusing on diabetes epidemiology.
She has presented at symposiums, including the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) and American Association of Clinical Endocrinologists (AACE) meetings and has also presented her research in national and international meetings.
She has received the Alfonso Rivera Research Award and the Young Investigator Award from the American Association of Clinical Endocrinology. She is a member of the Mexican National Academy of Medicine.
Dr Mehta has authored and co-authored publications in international journals in addition to numerous book chapters. She is the editor in chief for Current Diabetes Reports and an associate editor for Diabetes Medicine and a reviewer for Diabetes Therapy. She is also a co-editor of a book for patients called ‘Living with Diabetes: A Practical Manual’ (currently 3rd edition).
Duality of interest: Dr Mehta has received speaker’s honorarium / fees from Novo Nordisk, Boehringer Ingelheim, Eli Lilly and Astra Zeneca and consultancy fees from Novo Nordisk and Boehringer Ingelheim.
Date: Summer 2023